12.24
前日終値:
$11.84
開ける:
$11.93
24時間の取引高:
544.79K
Relative Volume:
0.58
時価総額:
$656.43M
収益:
$59,000
当期純損益:
$-84.74M
株価収益率:
-2.1023
EPS:
-5.8222
ネットキャッシュフロー:
$-59.69M
1週間 パフォーマンス:
-8.86%
1か月 パフォーマンス:
-23.83%
6か月 パフォーマンス:
-8.31%
1年 パフォーマンス:
-11.94%
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Compare AVTX vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
AVTX
Avalo Therapeutics Inc
|
12.24 | 656.43M | 59,000 | -84.74M | -59.69M | -5.8222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
508.15 | 128.80B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
238.82 | 95.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
799.63 | 82.33B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
851.39 | 53.54B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
373.90 | 42.30B | 5.76B | 514.49M | 1.10B | 4.4813 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-06 | 開始されました | Leerink Partners | Outperform |
| 2026-06-12 | 開始されました | BofA Securities | Buy |
| 2026-04-09 | 開始されました | Wolfe Research | Outperform |
| 2026-04-06 | 開始されました | Citizens | Mkt Outperform |
| 2026-02-02 | 開始されました | Guggenheim | Buy |
| 2025-12-18 | 開始されました | Mizuho | Outperform |
| 2025-09-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-09-05 | 開始されました | TD Cowen | Buy |
| 2025-08-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-02 | 再開されました | H.C. Wainwright | Buy |
| 2025-03-25 | 開始されました | Jefferies | Buy |
| 2025-03-25 | 開始されました | Stifel | Buy |
| 2025-02-28 | 開始されました | Piper Sandler | Overweight |
| 2025-02-21 | 開始されました | Wedbush | Outperform |
| 2024-12-19 | 開始されました | BTIG Research | Buy |
| 2024-10-24 | 開始されました | H.C. Wainwright | Neutral |
| 2024-04-16 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-09-24 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Avalo Therapeutics Inc (AVTX) 最新ニュース
In lieu of Board fees, Avalo Therapeutics (AVTX) grants Rita Jain 1,322 fully vested stock options. - Stock Titan
1,352 fully vested options replace Board fees for Avalo Therapeutics (AVTX) director Kevin Robert Lind. - Stock Titan
In lieu of board fees, Avalo Therapeutics (AVTX) grants Ron M. Philip 1,109 stock options. - Stock Titan
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Three new hires receive options to buy Avalo shares for $15.47 each - Stock Titan
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Avalo Therapeutics CFO Christopher Sullivan Executes Option Exercise and Sells 12,394 Shares via 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CFO sells 12K shares after option exercise - Stock Titan
AVTX 8-K FilingsAvalo Therapeutics, Inc. SEC 8-K - Stock Titan
Avalo Therapeutics (AVTX) CFO sells shares at $17.62 average, keeps 105K options - Stock Titan
Avalo Therapeutics at Cantor conference: building around il-1 beta By Investing.com - Investing.com Canada
(AVTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Avalo Therapeutics Inc. (AVTX) Peer Comparison – Compare with Others - Value Research
Avalo Therapeutics Inc. (AVTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX) - Seeking Alpha
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Six new hires get options to buy 78,000 Avalo shares - Stock Titan
Avalo Therapeutics Inc. (AVTX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Avalo Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com South Africa
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock - Investing.com
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com Nigeria
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com India
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com UK
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock - Investing.com
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Australia
Avalo Therapeutics (AVTX) CMO trades shares under 10b5-1 plan - Stock Titan
Avalo Therapeutics Inc. (AVTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
How Avalo Therapeutics Inc. (AVTX) Affects Rotational Strategy Timing - Stock Traders Daily
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares By Investing.com - Investing.com Nigeria
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - Investing.com India
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com Nigeria
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com India
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com UK
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - investing.com
AVTX | Avalo Therapeutics, Inc. Common FinancialsRevenue Breakdown - quiverquant.com
Avalo Therapeutics, Inc. Revenue Breakdown – NASDAQ:AVTX - TradingView
Deep Track Capital, LP Expands Avalo Therapeutics Inc (AVTX) Sta - GuruFocus
Avalo (AVTX) Q2 2026 Earnings: The EPS Result Is Below Expectation in the Latest Session; Post-Report: Shares Move 5.28% UpRevenue Growth Outlook - vinanet.vn
Avalo Therapeutics CMO Mittie Doyle Executes Stock Option and Sells 1,000 Shares Under 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CMO sells 1,000 shares in plan - Stock Titan
Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing - marketscreener.com
Avalo Therapeutics (AVTX) CFO sells 72K shares in 10b5-1 trades - Stock Titan
Avalo (AVTX) Financial Update: Profit Per Share Falls Below Its Benchmark in Latest Trading; Post-Report - vinanet.vn
Avalo Therapeutics CFO Christopher Ryan Sullivan Executes Stock Options and Sells Shares Over Two Days - Kalkine Media
Avalo Therapeutics (NASDAQ: AVTX) insider lines up new stock sale after $74K August trade - Stock Titan
Avalo Therapeutics (AVTX) insider lines up $98.7K stock sale - Stock Titan
Avalo Therapeutics Inc (AVTX) 財務データ
収益
当期純利益
現金流量
EPS
Avalo Therapeutics Inc (AVTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer |
Sep 16 '26 |
Sale |
16.33 |
12,394 |
202,437 |
39,900 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Sep 10 '26 |
Option Exercise |
8.04 |
10,185 |
81,887 |
50,085 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Sep 10 '26 |
Sale |
17.62 |
10,185 |
179,457 |
39,900 |
| Doyle Mittie | Chief Medical Officer |
Aug 28 '26 |
Sale |
20.00 |
679 |
13,580 |
51,776 |
| Doyle Mittie | Chief Medical Officer |
Aug 28 '26 |
Option Exercise |
8.04 |
679 |
5,459 |
52,455 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 18 '26 |
Option Exercise |
9.88 |
31,031 |
306,586 |
70,931 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 18 '26 |
Sale |
20.05 |
31,031 |
622,324 |
39,900 |
| CHRISTOPHER RYAN SULLIVAN | Officer |
Aug 18 '26 |
Proposed Sale |
20.05 |
31,031 |
622,221 |
0 |
| CHRISTOPHER RYAN SULLIVAN | Officer |
Aug 17 '26 |
Proposed Sale |
19.59 |
70,709 |
1,385,189 |
0 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 17 '26 |
Option Exercise |
9.88 |
40,821 |
403,311 |
81,594 |
大文字化:
|
ボリューム (24 時間):